Jump to content

LUNGevity Blog - Progress in Targeting MET Drivers in Advanced NSCLC


Recommended Posts

Progress in Targeting MET Drivers in Advanced NSCLC

Posted on March 4, 2022
Juhi Kunde, MA, LUNGevity Science WriterDr. Edward Garon

MET is a gene that encodes for a MET protein. It is an important signaling protein known to play many different important roles, from the development of embryos to wound healing in adults. However, when specific MET gene alterations occur, they can also lead to the development of non-small cell lung cancer (NSCLC).

Among patients with NSCLC, approximately 3%-4% have these specific MET alterations. Researchers have developed treatments that target these altered MET pathways and shrink tumors. Two of these targeted therapies have been approved by the US Food and Drug Administration (FDA).

LUNGevity Foundation spoke with Edward Garon, MD, director of thoracic oncology at the UCLA Jonsson Comprehensive Cancer Center and member of LUNGevity’s Scientific Advisory Board, to learn more about MET targeted therapies and the exciting future of MET-based treatments. 

Read more of the blog here:


Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.